Purpose Triflusal is an antiplatelet agent that irreversibly acetylates cyclooxygenase isoform 1 (COX-1) and therefore inhibits thromboxane biosynthesis. It was initially marketed as capsules containing 300 mg of active substance. In 2006 a new 600 mg (10 ml) oral solution form of triflusal was authorized in Spain. The primary aim of this study was to compare the gastrointestinal safety of the new triflusal oral solution with triflusal capsules in healthy volunteers. Methods Sixty healthy subjects were randomly assigned, in a 2.5:2.5: 1 ratio, into one of three groups, with 25 subjects receiving one bottle of triflusal oral solution (600 mg) daily, 25 subjects receiving two triflusal capsules (600 mg) once daily, and ten subjects receiving two placebo capsules once daily, respectively, during 7 consecutive days. Gastroscopy was performed at baseline before the administration of study drugs and after 4-8 h of the last dose of study drugs. Effects on the esophagus, stomach, and duodenum were measured in accordance with a modified Lanza scale. Results No differences between groups were detected at baseline. After treatment, median global scores in the placebo, triflusal solution, and triflusal capsules groups were, respectively, 0, 1, and 3 (p=0.003 for comparison between placebo and triflusal capsules and p=0.042 for comparison between triflusal solution and triflusal capsules). There were no significant differences between the scores on the triflusal solution and placebo groups. All treatments were well tolerated. Conclusion In healthy subjects, triflusal solution induced less endoscopically apparent gastrointestinal mucosal damage than triflusal capsules and did not induce more damage than the placebo in healthy volunteers.
Introduction
Triflusal is an antiplatelet agent marketed in 1981 as capsules containing 300 mg of active substance. Triflusal irreversibly acetylates cyclooxygenase isoform 1 (COX-1) and therefore inhibits thromboxane biosynthesis [1, 2] . Unlike acetylsalicylic acid (ASA), triflusal inhibits phosphodiesterase, the enzyme responsible for degrading cAMP and cGMP, both of which have antiaggregant effects [3] . Also unlike ASA, the endothelial synthesis of prostacyclin is preserved with triflusal [1] . The authorized posology of triflusal capsules is 600 mg (two capsules) in a single daily dose or 900 mg (three capsules) in fractionated daily doses.
In controlled clinical trials involving patients with acute myocardial infarction [4] and patients with ischemic stroke or transient ischemic attack [5, 6] , triflusal administered at a dose of 600 mg daily has demonstrated an efficacy similar to ASA in the prevention of vascular events but with a lower hemorrhagic risk. These results were confirmed in a meta-analysis [7] . The efficacy and tolerability of triflusal in patients with unstable angina [8] , aortocoronary bypass [9] , bioprosthetic valve replacement [10] , and peripheral arterial disease [11] have also been evidenced in controlled clinical trials. The association of triflusal and moderate intensity oral anticoagulation is more effective than standard oral anticoagulation in the prevention of vascular events in patients with atrial fibrillation [12] . Triflusal is well tolerated in patients with ASA-induced asthma [13] .
The gastrointestinal tolerability of triflusal is good. In the Triflusal versus Aspirin in Cerebral Infarction Prevention (TACIP) study [5] , performed in 2113 patients who had suffered an ischemic stroke or transient ischemic attack in the previous 6 months, the incidence of gastrointestinal hemorrhage was lower with triflusal than with aspirin ( 4.6 vs 7.6%; p=0.005), as was the incidence of peptic ulcer (0.1 vs 0.8%; p=0.021). However, the incidence of dyspepsia was higher with triflusal than with aspirin (27.4 vs 21.7%; p= 0.002). Results from the previously mentioned meta-analysis [7] demonstrated that gastrointestinal hemorrhage was higher with aspirin than with triflusal [odds ration (OR) 1.83; 95% confidence interval (CI) 1.35-2.48] whereas non-hemorrhagic gastrointestinal adverse events were lower with aspirin than with triflusal (OR 0.84; 95% CI 0.75-0.95) [7] . In casecontrol studies [14, 15] , triflusal has not been associated with a significant risk of gastrointestinal hemorrhage.
A new oral 600 mg (10 ml) oral solution form of triflusal that demonstrates bioequivalence with triflusal 600 mg capsules [16] was authorized for use in Spain in 2006.
The primary aim of this study was to compare the gastrointestinal safety of triflusal oral solution with triflusal capsules in healthy volunteers by means of upper endoscopy evaluation. As secondary objectives, the gastrointestinal safety of triflusal oral solution and triflusal capsules were compared with placebo in a diverse sample of healthy volunteers.
Subjects and methods

Subjects
Sixty healthy subjects (31 men, 29 women; mean age 25.8 years; age range, 20-42 years) participated in the study. Before entering the study, all subjects were required to provide a complete medical history and undergo a physical examination, electrocardiogram (ECG), and clinical laboratory tests. Subjects were excluded from the study if they met some of the following criteria: history of gastrointestinal disease or current gastrointestinal symptoms; abnormal results concerning vital signs (systolic and diastolic blood pressure, heart rate and body temperature) or ECG; being a smoker; alcohol or drug abuse in the previous month or positive urine test for ethanol, cannabis, cocaine, amphetamines, benzodiazepines, or opiates; antecedent of hypersensitivity to drugs; consumption of stimulant beverages (>5 cups/glasses coffee, tea, or cola beverages per day) in the week immediately preceding the endoscopic examination; intake of any other medication (including over-the-counter and herbal medicines) in the two previous weeks; seropositivity for hepatitis B or C viruses or human immunodeficiency virus (HIV); positive test for Helicobacter pylori; history of cardiovascular, respiratory, renal, hepatic, endocrine, hematologic or neurological disease, or other chronic diseases; surgical intervention in the previous 6 months; pregnancy or women not using an effective contraceptive method; participation in another clinical trial during the previous 3 months; being a blood donor in the previous 4 weeks. Moreover, subjects were excluded if the baseline endoscopy revealed abnormal findings (endoscopic score>1, see below).
Study design
The study was conducted using a randomized, active and placebo controlled, parallel-group design, with a blind evaluator.
Evaluation of the inclusion and exclusion criteria was carried-out during the 3 weeks prior to the start of the study. This evaluation included anamnesis, physical exam, ECG, blood analysis (hematology, biochemistry and serologies for hepatitis B and C viruses and for HIV), a 13 C-urea breath test for Helicobacter pylori (UB Test, Otsuka Pharmaceutical, S.A., Barcelona, Spain), urine tests for abuse drugs, and pregnancy test in women. During the 24 h previous to treatment, an endoscopic examination to rule-out previous pathology was performed.
Subjects were randomly assigned, in a 2.5:2.5: 1 ratio, to one of three groups, with one group receiving one bottle of triflusal oral solution (600 mg) daily, one group receiving two triflusal capsules (600 mg) once daily, and one group receiving two placebo capsules once daily. Randomization was performed from a computer-generated balanced list based on the above-mentioned distribution. The study medications were administered daily in the Clinical Pharmacology Department of the Hospital de la Santa Creu I Sant Pau (Barcelona) during 7 consecutive days. The solution and capsules were taken at 8 a.m. during the first 6 days and at 10 a.m. on the last day (day 7). Both capsules and oral solution were taken with 220 ml of water.
Prior to study commencement all participants gave informed written consent, and approval was obtained from the Ethical Committee of the Hospital de la Santa Creu I Sant Pau (Barcelona) as well as from the Spanish Health Authorities.
Assessment
Endoscopies were performed 4-8 h after administration of the last dose of study drugs, using an Olympus or Pentax video gastroscope ( Olympus Europe, Hamburg Germany). All subjects received sedation with midazolam (dose 2 mg) or propofol (doses ranged between 70 and 260 mg) immediately before endoscopic intubation. The esophagus, the entire stomach, and duodenum were systematically examined in a proximal to distal manner. Each endoscopic procedure was documented by photographs. Hemorrhagic and erosive mucosal lesions were graded using the standard score scale devised by Lanza [17] and modified by the Gastroenterology Department of the Hospital de la Santa Creu I Sant Pau (Barcelona). Scores were assigned as follows: normal, 0 points; erythema, 1 point; one to three erosions or petechiae, 2 points; four to five erosions or petechiae, 3 points; six to ten erosions or petechiae, 4 points; more than ten erosions or petechiae, 5 points; ulcer, 6 points. Separate endoscopic injury scores were assessed (assigned) for the esophagus, stomach, and duodenum until the second portion. The median scores for each of the three treatment groups were calculated. Gastroscopies were documented with photographs. Two endoscopists (SS and J Ba) were involved in the study. In each volunteer basal and final endoscopies were performed by the same endoscopist who was blinded to the assigned treatment.
Subjects were provided a diary card in which they were asked to register the following symptoms: heartburn, dysphagia, regurgitation, abdominal bloating, nausea, and epigastric pain. The intensity of these symptoms was scored as follows: absence, 0; mild, 1; moderate, 2; severe, 3. These symptoms were also assessed by means of a visual analogic scale (VAS) of 100 mm in which 0 was absence of symptoms and 100 the poorest possible symptom. Patients filled in the VAS from day 1 to day 7, after medication intake.
Blood analysis (hematology and biochemistry) and ECG were repeated at 24-72 h following the last dose of study drugs.
All reported adverse events and abnormal laboratory findings were recorded and tabulated by treatment group. Causality relationship was defined according to the World Health Organization criteria [18] .
Statistical analysis
Based on the results of Fiorucci et al. [19] , a sample of 50 subjects (25 in each of the active treatment arms) would be required to achieve a 80% power to detect a difference of 1.65 points between triflusal oral solution and triflusal capsules in the modified Lanza scale. A sample of ten subjects in the placebo group was also included for comparison with the active drugs.
Main and secondary variables were analyzed by means a Kruskal-Wallis test comparing the three study treatments. When differences were found, comparisons between groups were analyzed by means a Mann-Whitney test. All analyses were performed with a two-sided significance level of 0.05.
Results
One hundred and fifteen volunteers participated in the screening visit, of whom 44 failed to meet the selection criteria (28 because H. pylori was present) and were excluded from the study. The remaining 71 subjects had an endoscopy screening with normal results at baseline. Of these, ten volunteers were considered as reserves and 61 (31 men) were included in the study. One subject dropped-out due to lack of compliance with the protocol and was not replaced. Sixty volunteers completed the study. Twenty-five received triflusal capsules, 25 received triflusal solution, and ten volunteers received placebo. The demographic characteristics of the study population are shown in Table 1 .
All endoscopies at baseline were considered normal in accordance with the inclusion and exclusion criteria, and all endoscopic scores were >1. When we used the modified Lanza scale, the median injury score at baseline was 0 for the three treatment groups, both globally and separately in the stomach, esophagus, and duodenum (Table 2) . No differences were found between groups. After treatment, median global scores in the placebo, triflusal solution, and triflusal capsules groups were 0, 1, and 3, respectively (p= 0.008 between three treatment groups, Kruskal-Wallis test; p = 0.003 for comparison between placebo and triflusal capsules, Mann-Whitney test; p=0.042 for comparison between triflusal solution and triflusal capsules, MannWhitney test). There were no significant differences between triflusal solution and placebo (p=0.212, MannWhitney test). When considered separately, median scores for esophagus or duodenum were 0 in the three treatment groups, whereas in the stomach, median scores for placebo, triflusal solution, and triflusal capsules were 0, 0, and 3, respectively (p=0.004 between three treatment groups, Kruskal-Wallis test; p =0.003 for comparison between placebo and triflusal capsules, Mann-Whitney test; p= 0.022 for comparison between triflusal solution and triflusal capsules, Mann-Whitney test). No significant differences were found between triflusal solution and placebo. Endoscopic scores after treatment are shown in Table 3 . An example of gastroduodenal endoscopies for each treatment is shown in Fig. 1 . Medians for symptoms in the VAS and in the diary cards for placebo, triflusal solution and triflusal capsules were 0 on all treatment days. Thus, no differences were detected concerning these variables.
Adverse events were reported in two, nine and seven volunteers in the placebo, triflusal solution, and triflusal capsules groups, respectively (Table 4 ). All adverse events were mild or moderate in intensity. None was serious and all subjects recovered.
Discussion
We conducted a proof of concept endoscopic and wellpowered study to compare the gastrointestinal safety of triflusal oral solution with triflusal capsules in healthy volunteers. As secondary objectives the gastrointestinal safety of triflusal oral solution and triflusal capsules were compared with placebo. Subjects enrolled in this study were well matched at baseline, with a median injury score of 0 for the three groups of treatment. The median global score in the triflusal capsules group after 7 days of treatment increased to 3, compared with an increase to 1 in subjects receiving triflusal solution and with an unchanged score of 0 in subjects receiving placebo. Therefore, our data provide convincing evidence that triflusal solution induces fewer visible changes in gastroduodenal mucosa than triflusal capsules in subjects without previous gastroduodenal disease. A possible explanation for these findings is that when triflusal is administered in a solid form (capsules) the degradation of the drug in the stomach can not be uniform, and local concentrations can be particularly high. In addition, the intrinsic acidity of triflusal is high, with a pKa value of 3.0. However, when triflusal solution is administered, a homogeneous distribution along the gastric mucosa is guaranteed, as well as a faster absorption [16] and, more important, a solution containing the sodium salt of triflusal (as is the case), with a pH between 6 and 7, does not produce the local effects caused by the strong acidity of the solid form (not sodium salt). In a recently published study [20] , performed in 609 patients undergoing chronic antiplatelet therapy who presented gastrointestinal disorders attributed to this therapy, mainly with aspirin, replacement of the initial antiplatelet therapy with triflusal solution improved the treatment tolerability and quality of life of the patients.
Gastrointestinal toxicity of antiplatelet agents, such as aspirin and clopidogrel, are well known. Even when administered at low doses, aspirin can cause serious gastrointestinal bleeding [21] . The most frequently reported adverse events in both the aspirin and clopidogrel groups in the CAPRIE [22] study were gastrointestinal events, although the incidence was lower with clopidogrel. In an attempt to decrease the incidence of serious gastrointestinal side effects associated to aspirin and clopidogrel, proton pump inhibitors (PPIs) are frequently prescribed concomitantly with these antiplatelet drugs. Accordingly, the American College of Cardiology/American Heart Association Guidelines in Unstable Angina/Non-ST Elevation Myocardial Infarction [23] recommends that in patients with a history of gastrointestinal bleeding, when aspirin or clopidogrel is administered alone or in combination, drugs to minimize the risk of recurrent gastrointestinal bleeding (e.g., PPIs) should be prescribed concomitantly (Class I, Level of Evidence: B). A report of the American College of Cardiology Foundation/ American College of Gastroenterology/American College of Cardiology recommends the administration of PPIs in patients receiving antiplatelet therapy if gastrointestinal risk factors are present [24] . There is emerging evidence that the concomitant administration of PPIs diminishes the antiplatelet effect [25] and the clinical efficacy of clopidogrel [26] . For the abovementioned reasons, it is convenient that alternative antiplatelet agents with a good gastrointestinal safety profile, such as triflusal, be available.
A major advantage of an antiplatelet drug in oral solution is its potential to be administered through a nasogastric tube, as can be the case of patients with ischemic stroke [27] . In this case, an antiplatelet drug in form of oral solution could be of interest. On the one hand, it avoids the process of titration of a solid antiplatelet drug, Endoscopic scores are given as the median value, with the minimum and maximum scores, respectively, given in parenthesis which is an alteration of the original pharmaceutical form, and on the other hand, it is time saving in terms of the patient's careers. Moreover, an oral solution can be also useful to be administered to patients with dysphagia to solids for any reason but needing treatment with antiplatelet drugs. In this sense, it is known that about 50% of institutionalized elderly people have swallowing disorders [28] . Our study has a number of limitations that should be noted. Firstly, it should be taken into account that changes in the gastroduodenal mucosa in this kind of study are not necessarily good predictors of major upper gastrointestinal complications. In this sense, it should be mentioned that results from several endoscopic studies carried out in healthy volunteers support the hypothesis that entericcoated aspirin causes less gastric erosion and microbleeding than regular formulations [29] [30] [31] but no clinical benefits of the former in terms of reducing gastrointestinal bleeding or ulceration have been successfully demonstrated, although endoscopic studies show that potentially these benefits could exist [32] . Secondly, the sample size was calculated from results of a previously published study [19] , whereas the assessment of hemorrhagic and erosive mucosal lesions A) Normal mucosa B) Normal mucosa C) Erosive mucosal lesions were grated using the standard score scale devised by Lanza [17] and modified by the Gastroenterology Department of the Hospital de la Santa Creu I Sant Pau (Barcelona). This approach is not the most desirable from a methodological point of view, but endoscopists participating in the study preferred the scale that they used daily to assess endoscopic results. Thirdly, the novel galenic presentation of triflusal improved the topical gastroduodenal toxicity but whether the lower endoscopically apparent mucosal damage of triflusal solution versus triflusal capsules signifies less major upper gastrointestinal complications remains to be elucidated. The global tolerability of both triflusal solution and triflusal capsules was good, with no serious adverse events reported.
In conclusion, in subjects without previous gastroduodenal disease, the triflusal solution induced less endoscopically apparent mucosal damage than triflusal capsules and did not induce more damage than placebo. Further studies will be required to confirm the long-term safety of triflusal solution in patients.
